Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade

Immune checkpoint inhibitors have demonstrated broad single-agent antitumor activity and a favorable safety profile that render them attractive agents to combine with other systemic anticancer therapies. Pancreatic cancer has been fairly resistant to monotherapy blockade of programmed cell death pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jun, Hendifar, Andrew, Tuli, Richard, Chuang, Jeremy, Cho, May, Chung, Vincent, Li, Daneng, Salgia, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174117/
https://www.ncbi.nlm.nih.gov/pubmed/30294755
http://dx.doi.org/10.1186/s40169-018-0210-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174117/
https://www.ncbi.nlm.nih.gov/pubmed/30294755
http://dx.doi.org/10.1186/s40169-018-0210-9

Ejemplares similares